Delayed diagnosis of fabry disease presenting as myocardial ischaemia

Hellenic Journal of Cardiology

Volumn 53, Issue 1, 2012, Pages 77-79

  Marcì, Marcello ^a   Duro, Giovanni ^b   Tuttolomondo, Bruno ^c   Pinto, Antonio ^c   Cirrincione, Vincenzo ^a   Sanfilippo, Nicola ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anderson Fabry disease; Coronary artery disease; Echocardiography

Indexed keywords

ACETYLSALICYLIC ACID; AGALSIDASE ALFA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLOBOTRIAOSYLCERAMIDE;

ADULT; ANGINA PECTORIS; ARTICLE; CASE REPORT; CORONARY ARTERY OBSTRUCTION; DELAYED DIAGNOSIS; FABRY DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; MITRAL VALVE REGURGITATION; PERCUTANEOUS CORONARY INTERVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 84856248941     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004; 34: 236-242.
2. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003; 138: 338-346.
3. Nagueh SF. Fabry disease. Heart. 2003; 89: 819-820.
4. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995; 333: 288-293.
5. Nagao Y, Nakashima H, Fukuhara Y, et al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clin Genet. 1991; 39: 233-237.
6. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002; 105: 1407-1411.
7. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004; 110: 1047-1053.
8. Hoffmann B, Mayatepek E. Fabry disease-often seen, rarely diagnosed. Dtsch Arztebl Int. 2009; 106: 440-447.
9. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007; 146: 77-86.
10. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008; 130: 367-373.
11. Kovarnik T, Mintz GS, Karetova D, et al. Intravascular ultrasound assessment of coronary artery involvement in Fabry disease. J Inherit Metabol Dis. 2008; 31: 753-760.
12. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan W. Cardiac microvascular pathology in Fabry disease. Circulation. 2009; 119: 2561-2567.
13. Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H. Fabry disease in patients with hypertrophic cardiomyopathy. Z Kardiol. 2002; 91: 992-1002.